Search Result

Results for "

amyloid block

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (15) 5-HT Receptor (1) Apoptosis (1) Autophagy (1) Beta-secretase (1) Caspase (1) Drug Derivative (1) EGFR (2) FAAH (1) Gap Junction Protein (1) Interleukin Related (1) NOD-like Receptor (NLR) (1) p38 MAPK (1) Pyk2 (1) Pyroptosis (1) Reactive Oxygen Species (ROS) (2) Reference Standards (2) Tau Protein (3) Transmembrane Glycoprotein (1) Tyrosine Hydroxylase (1) α-synuclein (3) γ-secretase (1)
By Research Areas:	Cancer (4) Inflammation/Immunology (3) Metabolic Disease (1) Neurological Disease (19)

By Targets:

Amyloid-β (15)

5-HT Receptor (1)

Apoptosis (1)

Autophagy (1)

Beta-secretase (1)

Caspase (1)

Drug Derivative (1)

EGFR (2)

FAAH (1)

Gap Junction Protein (1)

Interleukin Related (1)

NOD-like Receptor (NLR) (1)

p38 MAPK (1)

Pyk2 (1)

Pyroptosis (1)

Reactive Oxygen Species (ROS) (2)

Reference Standards (2)

Tau Protein (3)

Transmembrane Glycoprotein (1)

Tyrosine Hydroxylase (1)

α-synuclein (3)

γ-secretase (1)

By Research Areas:

Cancer (4)

Inflammation/Immunology (3)

Metabolic Disease (1)

Neurological Disease (19)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: Amyloid-β

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14176

Compound E Maximum Cited Publications 17 Publications Verification γ-Secretase-IN-1	γ-secretase	Cancer
Compound E is a γ-secretase inhibitor. Compound E blocks β-amyloid(40), β-amyloid(42), and Notch γ-secretase cleavage with IC₅₀s of 0.24, 0.37, 0.32 nM, respectively.

HY-101855

Emrusolmin Anle138b	Amyloid-β	Neurological Disease
Emrusolmin (Anle138b), an oligomeric aggregation inhibitor, blocks the formation of pathological aggregates of prion protein (PrPSc) and of α-synuclein (α-syn). Emrusolmin strongly inhibits oligomer accumulation, neuronal degeneration, and disease progression in vivo. Emrusolmin has low toxicity and an excellent oral bioavailability and blood-brain-barrier penetration. Emrusolmin blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology .

HY-16009

Buntanetap (+)-Phenserine; ANVS401	α-synuclein	Neurological Disease Inflammation/Immunology
Buntanetap ((+)-Phenserine) is a selective acetylcholinesterase inhibitor. Buntanetap is a multiple neurotoxic protein translation inhibitor with oral activity, including amyloid precursor protein (APP), α-synuclein (αSYN) and huntingtin protein (HTT). Buntanetap reduces the production of β-amyloid precursor protein by blocking its mRNA translation. Buntanetap has anti-inflammatory effects and can be used in the study of Alzheimer's disease and Parkinson's disease .

HY-113788

PF-719	Pyk2 p38 MAPK Amyloid-β	Neurological Disease Inflammation/Immunology
PF-719 is a highly selective Pyk2 inhibitor with an IC₅₀ value of 17 nM. PF-719 promotes the activation of LKB1 and p38 MAPK. PF-719 blocks synaptic deficits induced by *Amyloid-beta* oligomers and reverses the inhibition of long-term potentiation induced by β-amyloid oligomers. PF-719 can be used in research related to Alzheimer's disease and autoimmune diseases .

HY-P991480

ONC-841	Transmembrane Glycoprotein Tau Protein Amyloid-β	Neurological Disease Cancer
ONC-841 is a blood-brain barrier-permeable, humanized monoclonal antibody targeting SIGLEC10. As an immune checkpoint inhibitor, ONC-841 restores the functions of immune effector cells such as T cells and enhances anti-tumor immune responses by blocking inhibitory signals mediated by SIGLEC10. ONC-841 restores the phagocytic and migratory activities of microglia, and promotes the phagocytosis of *Amyloid-β* and Tau protein aggregates by microglia. ONC-841 is applicable to research related to solid tumors and Alzheimer's disease .

HY-116753

(-)Clausenamide	Amyloid-β Tau Protein	Neurological Disease
(-)Clausenamide is an active alkaloid isolated from the leaves of Clausena lansium (Lour.) Skeels, and improves cognitive function in both normal physiological and pathological conditions. (-)Clausenamide inhibits *β-amyloid* (Aβ) toxicity, blocking neurofibrillary tangle formation by inhibiting the phosphorylation of tau protein. (-)Clausenamide exerts a significant neuroprotective activity against Aβ_25-35. (-)Clausenamide can be used for researching Alzheimer's disease (AD) .

HY-B1588

Carbenoxolone 5+ Cited Publications	Amyloid-β Gap Junction Protein	Neurological Disease Metabolic Disease
Carbenoxolone is a blood-brain barrier-permeable Pannexin1 inhibitor, gap junction (Gap junction) blocker, and *β-amyloid* 42** inhibitor. Carbenoxolone modulates voltage-gated currents of wild-type and mutant Panx1, and inhibits stimulus-activated Panx1 channel function. Carbenoxolone interacts with stable residues of β-amyloid 42 peptides, fibrils and oligomers, thereby inhibiting their aggregation. Carbenoxolone alleviates liver fibrosis. Carbenoxolone exerts neuroprotective and nootropic effects. Carbenoxolone can be used in studies related to Alzheimer's disease and liver fibrosis .

HY-103442

CGP52411 1 Publications Verification DAPH	EGFR Amyloid-β	Neurological Disease Cancer
CGP52411 (DAPH) is a high selective, potent, orally active and ATP-competitive EGFR inhibitor with an IC₅₀ of 0.3 μM. CGP52411 blocks the toxic influx of Ca ²⁺ ions into neuronal cells, and dramatic inhibits and reverses the formation of *β-amyloid* (Aβ42)** fibril aggregates associated with Alzheimer's disease .

HY-P4886A

Amyloid β-Protein (3-42) TFA	Amyloid-β	Neurological Disease
Amyloid β-Protein (3-42) TFA is a precursor of Pyr peptide. Pyroglutamic acid-modified Aβ (pEAβ) (3-42) is the core of the amyloid plaque in Alzheimer's disease. pEAβ (3-42) accelerates the aggregation of Aβ(1-42), while Aβ(1-42) significantly slows down the primary and secondary nucleation of pEAβ(3-42).

HY-16009B

Buntanetap L-Tartrate (+)-Phenserine L-Tartrate; ANVS401 L-Tartrate	Amyloid-β	Neurological Disease
Buntanetap L-Tartrate (Phenserine L-Tartrate) is a selective AChE inhibitor (IC₅₀ = 22.2 nM). Buntanetap is a multiple neurotoxic protein translation inhibitor with oral activity, including amyloid precursor protein (APP), α-synuclein (αSYN) and huntingtin protein (HTT). Buntanetap reduces the production of β-amyloid precursor protein by blocking its mRNA translation. Buntanetap has anti-inflammatory effects and can be used in the study of Alzheimer's disease and Parkinson's disease .

HY-P4886

Amyloid β-Protein (3-42)	Amyloid-β	Neurological Disease
Amyloid β-Protein (3-42) is the precursor of Pyr peptide. Pyroglutamate-modified Aβ (pEAβ) (3-42) is the core of the amyloid template block in Alzheimer's disease. pEAβ(3-42) accelerated the aggregation of Aβ(1-42), while Aβ(1-42) significantly slowed the primary and secondary nucleation of pEAβ(3-42) .

HY-170658

AChE-IN-80	Autophagy Amyloid-β Reactive Oxygen Species (ROS)	Neurological Disease Inflammation/Immunology
AChE-IN-80 (Compound 1) is an acetylcholinesterase (AChE) inhibitor. AChE-IN-80 can inhibit inflammation and the production of reactive oxygen species (ROS) in vitro- cultured neurons and microglia, trigger autophagy responses, and block the propagation of β-amyloid (Aβ) fibrils. AChE-IN-80 possesses antioxidant activity and neuroprotective effects and can be used in the study of Alzheimer's disease .

HY-123357

IMM-H004	Apoptosis	Neurological Disease
IMM-H004, a coumarin derivative, possesses neuroprotective and potent free radical scavenging abilities. IMM-H004 significantly inhibits amyloid-β (Aβ)-induced cytotoxicity and apoptosis, offering potential value for research into neurodegenerative diseases such as Alzheimer's disease. Additionally, IMM-H004 is also capable of effectively blocking the calcium mobilization and chemotaxis induced by CKLF1-C27 (HY-P3418), thereby alleviating asthmatic pathological changes in the lung tissue of CKLF1 transgenic mice .

HY-N13064

2,2′,4,4′-Tetrahydroxychalcone	Drug Derivative Beta-secretase Amyloid-β	Neurological Disease
2,2′,4,4′-Tetrahydroxychalcone (Compound 18) is a selective and potent BACE1 inhibitor with an IC₅₀ of 0.62 μM. 2,2′,4,4′-Tetrahydroxychalcone is a derivative of Isoliquiritigenin (HY-N0102) found in Glycyrrhiza uralensis. 2,2′,4,4′-Tetrahydroxychalcone can block the β-cutting step of amyloid precursor protein (APP), thereby reducing the production of *β-amyloid* (Aβ) peptide. 2,2′,4,4′-Tetrahydroxychalcone can be used for research of Alzheimer’s disease .

HY-101855R

Emrusolmin (Standard) Anle138b (Standard)	Reference Standards Amyloid-β	Neurological Disease
Emrusolmin (Standard) (Anle138b (Standard)) is the analytical standard of Emrusolmin (HY-101855). This product is intended for research and analytical applications. Emrusolmin (Anle138b), an oligomeric aggregation inhibitor, blocks the formation of pathological aggregates of prion protein (PrPSc) and of α-synuclein (α-syn). Emrusolmin strongly inhibits oligomer accumulation, neuronal degeneration, and disease progression in vivo. Emrusolmin has low toxicity and an excellent oral bioavailability and blood-brain-barrier penetration. Emrusolmin blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology .

HY-103442R

CGP52411 (Standard) DAPH (Standard)	Reference Standards EGFR Amyloid-β	Neurological Disease Cancer
CGP52411 (Standard) is the analytical standard of CGP52411 (HY-103442). This product is intended for research and analytical applications. CGP52411 (DAPH) is a high selective, potent, orally active and ATP-competitive EGFR inhibitor with an IC₅₀ of 0.3 μM. CGP52411 blocks the toxic influx of Ca2+ ions into neuronal cells, and dramatic inhibits and reverses the formation of β-amyloid (Aβ42) fibril aggregates associated with Alzheimer's disease .

HY-182328

BTA-EG6	Amyloid-β	Neurological Disease
BTA-EG6 is a brain-penetrant aggregated *amyloid-β* (Aβ) peptide binder with a K_d of 290 nM for Aβ1-42. BTA-EG6 binds to aggregated Aβ and forms protein-resistive coatings that block interactions between Aβ and catalase. BTA-EG6 protects neuroblastoma cells from Aβ-induced toxicity and oxidative stress, and inhibits Aβ-induced increases in cellular hydrogen peroxide (H₂O₂) levels. BTA-EG6 can be used for the research of alzheimer’s disease (AD) .

HY-P11581

MNP2	NOD-like Receptor (NLR) Interleukin Related Caspase Amyloid-β Tau Protein α-synuclein Pyroptosis	Neurological Disease
MNP2 is a NLRP3-ASC interaction inhibitor. MNP2 selectively binds to the PYD domain of ASC (K_a=149 nM) and blocks ASC-PYM binding (K_a=58 nM), thereby inhibiting the interaction between ASC and NLRP3 and suppressing the formation of the NLRP3 inflammasome. MNP2 inhibits IL-1β release and caspase-1 maturation, and reduces the efflux of potassium and chloride ions. MNP2 prevents mitochondrial damage and reactive oxygen species production, and significantly decreases NLRP3 inflammasome formation in neurodegenerative pathologies induced by *β-amyloid, Tau protein* and α-synuclein. MNP2 is applicable for the research of neurodegenerative diseases .

HY-182893

SK-129	α-synuclein Reactive Oxygen Species (ROS) Tyrosine Hydroxylase	Neurological Disease
SK-129 is a blood-brain barrier-permeable inhibitor of α-synuclein (αS) oligomers with a K_d of 221 nM. SK-129 preferentially binds to neurotoxic αS oligomers over physiological αS monomers, inhibits αS aggregation, blocks the interaction and co-aggregation of αS with tau protein, and prevents the maturation of αS-tau condensates into amyloid aggregates. SK-129 reduces ROS production, rescues dopaminergic neuron degeneration, improves motor function, restores endogenous dopamine synthesis, increases the number of Tyrosine Hydroxylase-positive neurons, prevents brain histopathological changes, alleviates neuroinflammation, and improves survival rates in relevant models. SK-129 can be used in research related to Parkinson's disease (PD) and Lewy body dementia (LBD) .

HY-183805

5-HT6R/FAAH modulator 2	5-HT Receptor FAAH	Neurological Disease
5-HT6R/FAAH modulator 2 is a dual 5-HT6R antagonist and FAAH inhibitor with human 5-HT6R pK_i 7.24, human FAAH pIC₅₀ 5.47, and blood-brain barrier penetration.5-HT6R/FAAH modulator 2 modulates serotonergic signaling, blocks 5-HT6R function, inhibits endocannabinoid degradation via FAAH catalytic activity suppression.5-HT6R/FAAH modulator 2 exhibits neuroprotective effects against mitochondrial dysfunction, amyloid-β, and glutamate-induced toxicity, reverses memory deficits.5-HT6R/FAAH modulator 2 shows reduced cytotoxicity relative to oxygen-containing lead compounds.5-HT6R/FAAH modulator 2 can be used for the research of Alzheimer's disease .

Cat. No.	Product Name	Target	Research Area